anim
anim
anim
  • All Categories
  • E-Services
  • NahdiNahdi Global
  • FlashFlash Sales
  • NahdicareNahdicare Health center
  • Home
  • Urinary Treatments
  • Incontinence
  • Genuine brands

    Genuine brands

  • Temperature Controlled

    Temperature Controlled

  • Secure Payment

    Secure Payment

About Product

Product Overview



  • Uridisitol 2mg is an antimuscarinic medicine indicated for Overactive Bladder Syndrome (OAB) in adults. It helps control urinary urgency, urge incontinence, urinary frequency and nocturia and is clinically proven to improve bladder control and quality of life.



Product Description



  • Active Ingredient: Tolterodine tartrate 2 mg (film-coated tablet).

  • Pack Size: 30 tablets (3 × 10 blister strips).

  • Appearance: White, round, biconvex tablets, debossed "J" on one side and "158" on the other.

  • Storage: Store below 30°C in original package.

  • Shelf Life: 24 months.




Mechanism of Action & Clinical Effects



  • Competitive antagonist of muscarinic receptors (M2 and M3) in detrusor muscle; active 5-hydroxymethyl metabolite contributes to effect. Inhibits involuntary bladder contractions, increases functional bladder capacity, delays initial urge and reduces urgency episodes.




Dosage & Administration



  • Standard Dose: 2 mg twice daily (1 tablet BID).

  • Reduced Dose: 1 mg twice daily (use in renal impairment CrCl ≤30 mL/min, moderate hepatic impairment, elderly with comorbidities, or when combined with potent CYP3A4 inhibitors).

  • Administration: With or without food; follow prescriber instructions.




Indications (SFDA Approved)



  • Urinary Urgency: Sudden compelling desire to pass urine difficult to defer.

  • Urge Incontinence: Involuntary leakage accompanied by or immediately preceded by urgency.

  • Urinary Frequency: ≥8 voids/24h.

  • Nocturia: Waking ≥1 time/night to void with impact on sleep.




Contraindications & Precautions



  • Absolute contraindications: Hypersensitivity to tolterodine/excipients, urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis/toxic megacolon.

  • Use with caution: Bladder outflow obstruction, GI disorders, renal/hepatic impairment, autonomic neuropathy.

  • Pregnancy/Lactation: Not recommended — insufficient human data.




Safety Profile & Adverse Events



  • Very common (≥10%): Dry mouth (≈35%).

  • Common (1–10%): Headache (12%), constipation (7%), dizziness (5%), abdominal pain (5%), dry eyes (3%), fatigue (4%).

  • Serious/rare: Urinary retention (<1%), cognitive impairment (rare, elderly), cardiac arrhythmias (very rare).




Drug Interactions



  • Contraindicated/Reduce dose: Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) — consider 1 mg BID.

  • Use with caution: Other anticholinergics, QT-prolonging agents, muscarinic agonists (e.g., bethanechol).




Clinical Evidence & Guidelines



  • Proven efficacy in landmark trials and real-world studies: 50–70% reduction in incontinence, 2–3 fewer daily voids, onset within 1–2 weeks and high patient satisfaction (70–80%). Recommended by AUA/SUFU (2024), EAU, NICE and CUA as an evidence-based option for OAB management..

Product Details:

    Incontinence
    Urinary Treatments
    Uridisitol

    Uridisitol 2 Mg - 30 Tablets

    52.85 SAR

    Uridisitol 2 Mg - 30 Tablets

    Product Overview



    • Uridisitol 2mg is an antimuscarinic medicine indicated for Overactive Bladder Syndrome (OAB) in adults. It helps control urinary urgency, urge incontinence, urinary frequency and nocturia and is clinically proven to improve bladder control and quality of life.



    Product Description



    • Active Ingredient: Tolterodine tartrate 2 mg (film-coated tablet).

    • Pack Size: 30 tablets (3 × 10 blister strips).

    • Appearance: White, round, biconvex tablets, debossed "J" on one side and "158" on the other.

    • Storage: Store below 30°C in original package.

    • Shelf Life: 24 months.




    Mechanism of Action & Clinical Effects



    • Competitive antagonist of muscarinic receptors (M2 and M3) in detrusor muscle; active 5-hydroxymethyl metabolite contributes to effect. Inhibits involuntary bladder contractions, increases functional bladder capacity, delays initial urge and reduces urgency episodes.




    Dosage & Administration



    • Standard Dose: 2 mg twice daily (1 tablet BID).

    • Reduced Dose: 1 mg twice daily (use in renal impairment CrCl ≤30 mL/min, moderate hepatic impairment, elderly with comorbidities, or when combined with potent CYP3A4 inhibitors).

    • Administration: With or without food; follow prescriber instructions.




    Indications (SFDA Approved)



    • Urinary Urgency: Sudden compelling desire to pass urine difficult to defer.

    • Urge Incontinence: Involuntary leakage accompanied by or immediately preceded by urgency.

    • Urinary Frequency: ≥8 voids/24h.

    • Nocturia: Waking ≥1 time/night to void with impact on sleep.




    Contraindications & Precautions



    • Absolute contraindications: Hypersensitivity to tolterodine/excipients, urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis/toxic megacolon.

    • Use with caution: Bladder outflow obstruction, GI disorders, renal/hepatic impairment, autonomic neuropathy.

    • Pregnancy/Lactation: Not recommended — insufficient human data.




    Safety Profile & Adverse Events



    • Very common (≥10%): Dry mouth (≈35%).

    • Common (1–10%): Headache (12%), constipation (7%), dizziness (5%), abdominal pain (5%), dry eyes (3%), fatigue (4%).

    • Serious/rare: Urinary retention (<1%), cognitive impairment (rare, elderly), cardiac arrhythmias (very rare).




    Drug Interactions



    • Contraindicated/Reduce dose: Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) — consider 1 mg BID.

    • Use with caution: Other anticholinergics, QT-prolonging agents, muscarinic agonists (e.g., bethanechol).




    Clinical Evidence & Guidelines



    • Proven efficacy in landmark trials and real-world studies: 50–70% reduction in incontinence, 2–3 fewer daily voids, onset within 1–2 weeks and high patient satisfaction (70–80%). Recommended by AUA/SUFU (2024), EAU, NICE and CUA as an evidence-based option for OAB management..

    Product Details:

      • Genuine brands

        Genuine brands

      • Temperature Controlled

        Temperature Controlled

      • Secure Payment

        Secure Payment

      Uridisitol 2 Mg - 30 Tablets